Trending
Investing in healthcare and biotech requires razor-sharp models, especially if you want to create more opportunities in this category through short selling. In today’s market, how can investors capitalize on short opportunities when AI, external Medicare Service pressure, policy regulation, and other factors are impacting healthcare investment targets and potentially derailing performance returns?
In our latest episode of the Thematic Investors podcast, we sit down with one of the great under-the-radar investors who has taken $3MM in AUM and has built it into a $1 BN firm. Join us in welcoming Dr. Michael Castor, CIO and Portfolio Manager, Sio Capital Management. Kieran and Michael discuss:
- What exactly turned him from an ENT resident into a career in finance.
- How the short-selling models at SIO Capital Management take a deep look at 4 critical aspects in the investment journey: Valuation, Catalysts, Sentiment, and Investment Narrative.
- Do Biotech investment targets simply go bankrupt, with investors holding the bag for returns that never materialize? Or is something else going on across the sector.
- With 17% of the U.S. GDP and 10% global GDP, where is healthcare headed, and what type of external forces are at play in driving efficiency?
- How will the U.S. administration balance drug prices, especially those that are significantly in the spotlight today like, Manjaro, Ozempic, and others?
- Has the bar on scientific assessment been lowered too far over the last few years, and can the drag on the healthcare system be reversed at this stage?
- The impact of AI and how new doctors will need to adjust their approaches in the next 5-10 years.
- and more.
Related: The Future of Hard Tech: A Billion-Dollar View from Analog Century